EP1148878A1 - 1,4,8,11-tetraazacyclotetradecane derivatives as radiodiganostic agents and their use in determining hypoxia and radioresistance of tumors - Google Patents
1,4,8,11-tetraazacyclotetradecane derivatives as radiodiganostic agents and their use in determining hypoxia and radioresistance of tumorsInfo
- Publication number
- EP1148878A1 EP1148878A1 EP00908353A EP00908353A EP1148878A1 EP 1148878 A1 EP1148878 A1 EP 1148878A1 EP 00908353 A EP00908353 A EP 00908353A EP 00908353 A EP00908353 A EP 00908353A EP 1148878 A1 EP1148878 A1 EP 1148878A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- complex
- cyclam
- derivative
- group
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- MDAXKAUIABOHTD-UHFFFAOYSA-N 1,4,8,11-tetraazacyclotetradecane Chemical class C1CNCCNCCCNCCNC1 MDAXKAUIABOHTD-UHFFFAOYSA-N 0.000 title claims abstract description 63
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 62
- 206010021143 Hypoxia Diseases 0.000 title claims abstract description 52
- 230000007954 hypoxia Effects 0.000 title abstract description 12
- 210000001519 tissue Anatomy 0.000 claims description 41
- 230000001146 hypoxic effect Effects 0.000 claims description 40
- 229910052751 metal Inorganic materials 0.000 claims description 33
- 239000002184 metal Substances 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- 125000005647 linker group Chemical group 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 238000003384 imaging method Methods 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- -1 2-nitroimidazol- 1-yl moiety Chemical group 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 239000013522 chelant Substances 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 229910052713 technetium Inorganic materials 0.000 claims description 6
- 229910052802 copper Inorganic materials 0.000 claims description 5
- 230000005855 radiation Effects 0.000 claims description 5
- 230000002285 radioactive effect Effects 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 229910052785 arsenic Inorganic materials 0.000 claims description 4
- 229910052804 chromium Inorganic materials 0.000 claims description 4
- 229910052733 gallium Inorganic materials 0.000 claims description 4
- 229910052738 indium Inorganic materials 0.000 claims description 4
- 229910052741 iridium Inorganic materials 0.000 claims description 4
- 229910052745 lead Inorganic materials 0.000 claims description 4
- 229910052748 manganese Inorganic materials 0.000 claims description 4
- 229910052750 molybdenum Inorganic materials 0.000 claims description 4
- 229910052759 nickel Inorganic materials 0.000 claims description 4
- 229910052758 niobium Inorganic materials 0.000 claims description 4
- 229910052763 palladium Inorganic materials 0.000 claims description 4
- 229910052697 platinum Inorganic materials 0.000 claims description 4
- 230000000717 retained effect Effects 0.000 claims description 4
- 229910052702 rhenium Inorganic materials 0.000 claims description 4
- 229910052703 rhodium Inorganic materials 0.000 claims description 4
- 229910052715 tantalum Inorganic materials 0.000 claims description 4
- 229910052721 tungsten Inorganic materials 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 229910052707 ruthenium Inorganic materials 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 2
- 230000004807 localization Effects 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 210000005013 brain tissue Anatomy 0.000 claims 1
- 150000004696 coordination complex Chemical class 0.000 claims 1
- 210000005003 heart tissue Anatomy 0.000 claims 1
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical group [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 241000700159 Rattus Species 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 14
- 239000013078 crystal Substances 0.000 description 12
- 239000003550 marker Substances 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000001110 calcium chloride Substances 0.000 description 6
- 229910001628 calcium chloride Inorganic materials 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000002600 positron emission tomography Methods 0.000 description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000009206 nuclear medicine Methods 0.000 description 5
- FWNOUYXMHAJQMU-DFAKLWRTSA-N (2s,3s,4s,5r)-2-(iodanylmethyl)-5-(2-nitroimidazol-1-yl)oxolane-3,4-diol Chemical compound O1[C@H](C[125I])[C@@H](O)[C@H](O)[C@@H]1N1C([N+]([O-])=O)=NC=C1 FWNOUYXMHAJQMU-DFAKLWRTSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 201000001514 prostate carcinoma Diseases 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 238000012879 PET imaging Methods 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002603 single-photon emission computed tomography Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- FWNOUYXMHAJQMU-DBRKOABJSA-N (2s,3s,4r,5r)-2-(iodomethyl)-5-(2-nitroimidazol-1-yl)oxolane-3,4-diol Chemical compound O1[C@H](CI)[C@@H](O)[C@@H](O)[C@@H]1N1C([N+]([O-])=O)=NC=C1 FWNOUYXMHAJQMU-DBRKOABJSA-N 0.000 description 2
- HIIJZYSUEJYLMX-UHFFFAOYSA-N 1-fluoro-3-(2-nitroimidazol-1-yl)propan-2-ol Chemical compound FCC(O)CN1C=CN=C1[N+]([O-])=O HIIJZYSUEJYLMX-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- AOYNUTHNTBLRMT-SLPGGIOYSA-N 2-deoxy-2-fluoro-aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](F)C=O AOYNUTHNTBLRMT-SLPGGIOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 238000011613 copenhagen rat Methods 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- BLNWTAHYTCHDJH-UHFFFAOYSA-O hydroxy(oxo)azanium Chemical compound O[NH+]=O BLNWTAHYTCHDJH-UHFFFAOYSA-O 0.000 description 2
- 239000012216 imaging agent Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- OBBCSXFCDPPXOL-UHFFFAOYSA-N misonidazole Chemical compound COCC(O)CN1C=CN=C1[N+]([O-])=O OBBCSXFCDPPXOL-UHFFFAOYSA-N 0.000 description 2
- 229950010514 misonidazole Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- LCTAABLXXZRHCO-UHFFFAOYSA-N 1-(4-bromo-2-nitroimidazol-1-yl)-3-methoxypropan-2-ol Chemical compound COCC(O)CN1C=C(Br)N=C1[N+]([O-])=O LCTAABLXXZRHCO-UHFFFAOYSA-N 0.000 description 1
- HIIJZYSUEJYLMX-JZRMKITLSA-N 1-fluoranyl-3-(2-nitroimidazol-1-yl)propan-2-ol Chemical compound [18F]CC(O)CN1C=CN=C1[N+]([O-])=O HIIJZYSUEJYLMX-JZRMKITLSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 150000004959 2-nitroimidazoles Chemical class 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000004459 Nitroreductase Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000008062 acetophenones Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical class C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 108020001162 nitroreductase Proteins 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000001389 radiobiologic effect Effects 0.000 description 1
- 230000000637 radiosensitizating effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 230000000287 tissue oxygenation Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- 229950004616 tribromoethanol Drugs 0.000 description 1
- 125000001814 trioxo-lambda(7)-chloranyloxy group Chemical group *OCl(=O)(=O)=O 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
Definitions
- This invention relates to derivatives of 1,4,8,11- tetraazacyclotetradecane (cyclam) which demonstrate hypoxic cell selectivity and retention and which are useful as radiodiagnostic agents for assessing tissue oxygenation status non-invasively, as well as to methods for preparing such derivatives and radionuclide metal-containing complexes thereof and their use for imaging and non-invasively determining tissue hypoxia and radioresi stance of tumors.
- Radiobiologic hypoxic fraction the fraction of clonogenic tumor cells that exhibit maximum radioresistance, has been shown to be an important parameter for predicting tumor treatment resistance and for the selection of aggressive and metastatic cell phenotypes. If this tumor property were known by clinicians at the time of diagnosis, it would be a useful predictor of tumor treatment response and would define subsets of patients for whom targeted therapies would produce improved cure rates.
- radiodiagnostic agents that can accurately assess the presence and extent of hypoxic tissues in tumors would be of invaluable assistance in designing the appropriate therapeutic regimen and in following the response of tumor tissue to therapy.
- various agents and methods have been proposed for the detection and measurement of hypoxic cells in tumors, and direct pO 2 measurements have been obtained from accessible tumors using microelectrodes, there is no practical, clinically useful diagnostic agent or method currently available.
- Some experimental procedures to assess tumor hypoxia are invasive, requiring multiple biopsy specimens that cannot always be obtained.
- hypoxic tissue A promising approach to the assessment of hypoxic tissue is suggested by the ability of certain classes of compounds to selectively localize in these tissues after intravenous administration.
- the radiosensitizing drug, misonidazole (MISO) was shown to become selectively bound to the macromolecular fraction of EMT-6 murine tumor and V-79 hamster lung cells in hypoxic in vitro incubation studies (J.D. Chapman et al., Cancer Res., 43: 1523- 1528 (1983)) and to EMT-6 tumors in BALB/C mice (B.M. Garrecht et al., Brit. J. Radiol., 56: 745-753 (1983)).
- MISO misonidazole
- hypoxic tissue imaging agents incorporating ⁇ -emitting radionuclides have been investigated. These include 4- bromomisonidazole (D.C. Jette et al., Int. J. Nucl. Med. Biol, 10: 205-210 (1983); J.S. Rasey et al., Radiat. Rse., 91: 542-554 (1982)), l-(2-iodophenoxy)- ethyl)-2-nitroimidazole (L.I. Wiebe, Nucelartechnike, 23: 63-67 (1984)), a series of iodinated acetophenone derivatives of 2-nitroimidazole (J.R.
- IAZA iodoazomycin arabinoside
- IAZGP iodoazomycin galactopyranoside
- IAZXP iodoazomycin xylopyranoside
- IAZGP and IAZA have been found to be selectively toxic to hypoxic EMT-6 tumor cells and also sensitize these cells to the lethal effects of ionizing radiation.
- IAZA is taken up preferentially in EMT-6 tumor tissue at a level useful for non-invasive imaging.
- I-IAZA An imaging study using 125 I-IAZA showed EMT-6 tumor tissue to be clearly delineated from surrounding tissue. More recently, pilot clinical studies using 123 I-IAZA with single photon emission computed tomography (SPECT) and 18 F-FMISO with positron emission tomography (PET) have been reported. These data were recently reviewed and it appears unlikely that either marker is optimal for routinely determining the HF of individual human tumors (J.D. Chapman et al., Radiother. Oncol., 46: 229-37 (1998)). Among the azomycin-nucleoside markers, IAZXP and IAZGP have been shown to exhibit the most favorable properties for marking the HF of solid rodent tumors in vivo (J.D. Chapman et al. (1988), supra).
- azomycin nucleosides and particularly IAZGP, have been found to have useful hypoxic marking properties, an extensive research effort is ongoing to identify hypoxic markers which exhibit good bioavailability to all tissues, low lipophilicity to promote rapid renal excretion, are amenable to detection at optimal times after administration and can be convenientily labelled with the preferred nuclear medicine isotopes.
- cyclam derivatives having the formula:
- the linking group comprises a chain of 2 to 7 atoms selected from the group of carbon or nitrogen, wherein the moiety connecting the cyclam nitrogen and the 1-imidazole nitrogen to the remainder of the linking group is a -CH 2 - moiety, the carbons in the remainder of the linking moiety being optionally substituted with a hydroxyl group, and two adjacent carbons in the linking groups being optionally replaceable by an amide group.
- Stereoisomers including both enantiomers, meso forms and diastereomers of the cyclam derivatives of the above general formula, as well as the pharmaceutically acceptable salts of such cyclam derivatives and their isomers, are included within the present invention.
- the present invention also provides radiodiagnostic complexes comprising a cyclam derivative, as described above, and various complex- forming radionuclide metals.
- a process for preparation of the cyclam derivatives of the invention. Briefly, this method involves the nucleophilic displacement by cyclam of a suitable leaving group on a moiety containing azomycin.
- the present invention provides radiodiagnostic compositions comprising the above-mentioned radionuclide metal-containing complexes and a biologically compatible carrier medium for use in determining tumor hypoxia and radioresistance, as well as in imaging body tissue of a living test subject.
- kits for carrying out such method.
- the kit contains
- a novel non-invasive method for the detection and measurement of tissue hypoxia in a mammal comprising the steps of:
- a method for imaging body tissue of a living test subject by administering to the test subject a radionuclide metal-containing complex, as described herein, and detecting the localization of the complex in the body tissue using a suitable radiation detector.
- a suitable radiation detector include, without limitation, SPECT and PET cameras.
- the cyclam derivatives of the present invention are considered superior to previously reported radiodiagnostic agents for measuring hypoxia and predicting tumor radioresistance because of their high specific activity and the large differential labelling of experimental tumors having a an HF of 15-20%, as compared to tumor tissue that exhibits no detectable HF.
- the ability to define one type of tumor resistance in advance of therapy is important, since various modalities of targeted cancer treatment, such as chemical radiosensitizers, chemopotentiation agents and bioreductive drugs, can now be directed towards treatment-resistant hypoxic cells.
- a radiodiagnostic agent for oxygenation status will be useful in detecting and defining other disease states, including myocardial infarct and cerebrovascular hemorrhage, in which ischemia and/or infarct play a role and in infections which involve anaerobic foci.
- FIGURE 1 is a graphical representation of typical marker biodistribution data obtained by measuring percentage of injected dose of marker/gram of assessed tissue (% ID/G) as a function of time for eight different tissues from five EMT6 tumor-bearing scid mice, up to 10 hours after intravenous
- FIGURES 2A-D show collimated, gamma-camera planar images of two pair of R 3327-AT (left; hypoxic) and R 3327-H (right; non-hypoxic) tumor-bearing rats six hours after i.v. administration of Tc-99m-labelled
- FIGURE 3 is a graphical representation of data showing the binding rate (dpm/10 6 cells/hr) of a Cu-64 containing tetra-[2-hydroxy-3-(2- nitroimidazol-l-yl)propyl]-substituted cyclam to tumor cells in vitro, as a function of oxygen concentration.
- FIGURES 4A and B show collimated, gamma camera planar images of a pair of R3327-AT (left; hypoxic) and R3327-H (right; non-hypoxic) tumor bearing rats 5-7 hours after administration of a Cu-64 containing tetra-[2- hydroxy-3-(2-nitroimidazol-l-yl)propyl]-substituted cyclam.
- cyclam derivatives of formula I can be prepared from known starting materials and the syntheses of specific embodiments of such derivatives that are within the scope of the invention are exemplified below. Certain of these derivatives have been used for radiodiagnostic imaging of animal tumor models and for evaluating their ability to determine tissue hypoxia and assess their hypoxic marking properties, as reported below.
- Suitable linking groups for linking the 2-nitro-imidazolyl moiety to the cyclam nucleus are those of the formula
- n is an integer from 1 to 6
- m is an integer from 1 to 6
- p is an integer from 1 to 6.
- At least one of the cyclam ring nitrogens is linked to a nitroimidazolyl moiety of the above formula through an unsubstituted or hydroxyl-substituted divalent alkylene linking moiety of 2 to 7 carbon atoms, which may optionally be interrupted by at least one group containing the amide moiety.
- Particularly preferred embodiments of the present invention are the mono-, di- and tetra-2-nitroimidazol-l-yl-substituted cyclam derivatives in which the nitroimidazolyl moiety is linked to the ring nitrogen of cyclam via a linkage having the structure -CH 2 -CH(OH)-CH 2 -.
- These particular derivatives have an asymmetric center in the linking moiety. This makes the mono- substituted compound resolvable into a pair of optical isomers.
- the di- and tetra-substituted derivatives are separable into d, 1 (racemic) and meso forms, which contain a plane of symmetry and, therefore, are resolvable into optical isomers.
- the cyclam derivatives of this invention can form soluble salts with pharmaceutically acceptable acids, such as hydrochloric, phosphoric, tartaric and citric acids, and these salts are also within the scope of the present invention.
- pharmaceutically acceptable salts of the cyclam derivatives described herein can be prepared following procedures that are familiar to those skilled in the art.
- the cyclam derivatives described herein form a complex with various radionuclide metals selected from the group of the radioactive isotopes of
- Tc Cu, Ru, Co, Pt, Fe, Os, Ir, W, Re, Cr, Mo, Mn, Ni, Rh, Pd, Nb, Pb, Ga, As, In and Ta, for example, Tc-99m, Cu-67, Cu-64, Cu-62, Pb-203, Ga-67, Ga-68, As- 72, In-I l l, In-113m, Ru-97, Fe-52, Mn-52m, Cn-51 and Co-57.
- Particularly preferred complex -forming radionuclide metals for use in the present invention are Tc-99m, Cu-67, Cu-64 and In-111.
- the complexes have a net positive charge and are associated with counter anions, which may be BF 4 -, ClO 4 -, Br-, CF 3 COO-, C1-, or the like, depending on the manner in which they are prepared.
- the radionuclide metal-containing complexes are prepared by causing a salt or chelate of a suitable radionuclide metal to undergo a complex-forming reaction with a cyclam derivative of the invention.
- Complex formation is effected by contacting the cyclam derivative with the desired metal in the form of a salt or in the form of a chelate wherein the metal is bound to a relatively weak chelator.
- the desired complex is formed via the principle of ligand exchange.
- a reducing agent may be required for the above reaction, as in cases where technetium metal is used.
- Suitable reducing agents for this purpose include Sn(LI) compounds, dithionites, sodium borohydride, and the like.
- the various reaction components may be conveniently provided in kit form. Because the radiodiagnostic composition of the present invention can be prepared in a sample manner, this process may be readily carried out by experienced researches or clinicians.
- kit will typically contain (i) a cyclam derivative of the general formula I, shown above, to which an inert biologically acceptable carrier medium and/or formulating agent(s), e.g., reducing agent(s), and/or auxiliary substance(s) may optionally be added, and (ii) instructions for carrying out a complex-forming reaction using the components present in the kit.
- an inert biologically acceptable carrier medium and/or formulating agent(s) e.g., reducing agent(s), and/or auxiliary substance(s) may optionally be added
- instructions for carrying out a complex-forming reaction using the components present in the kit e.g., reducing agent(s), and/or auxiliary substance(s)
- the desired radionuclide may be contacted with cyclam derivative in the form of a chelate, bound to a relatively weak chelator, such as a glucoheptonate, pyrophosphate, a polyphosphate, a phosphonate or polyphosphonate, an oxinate, a carboxylate, a hydroxycarboxylate, an aminocarboxylate, an enolate or a mixture thereof, such reaction being carried out under moderate conditions.
- a relatively weak chelator such as a glucoheptonate, pyrophosphate, a polyphosphate, a phosphonate or polyphosphonate, an oxinate, a carboxylate, a hydroxycarboxylate, an aminocarboxylate, an enolate or a mixture thereof, such reaction being carried out under moderate conditions.
- the kit embodiment of this invention may optionally comprise a solution of the radionuclide metal. Because such solutions have a limited shelf life, however, they may be made available separately.
- the components of the above-described kit may be supplied as a solution, for example, in the form of a physiological saline solution, or in a buffer solution. If desired, the above-mentioned components may be stabilized in a usual way with suitable stabilizers such as ascorbic acid, gentisic acid or salts of these acids.
- Radiodiagnostic compositions comprising a radionuclide metal- containing complex, as described above, may be conveniently formulated for administration with a biologically acceptable carrier medium.
- the carrier medium is sterile, pyrogen-free phosphate buffered sale (PBS).
- the radiodiagnostic agents of the invention should be delivered to tissue in trace amounts, on the order of 10 "12 M.
- Nuclear medicine markers are usually administered according to their biodistribution, with isotope dose up to 40 mCi in the case of Tc-99m, for example.
- any substance used in formulating a radiodiagnostic composition in accordance with this invention should be virus-free, pharmaceutically pure and substantially non- toxic in the amount used.
- the risk of contaminating microorganisms may be prevented by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, surbic acid, thimerosal or the like. It may also be beneficial to include in the formulation isotonic agents such as glucose.
- biologically acceptable carrier medium is intended to include any and all solvents, dispersion media and the like which may be appropriate for the desired route of administration of the composition.
- radiodiagnostic agents of the invention are administered parenterally, intravenous administration being the preferred route.
- radiodiagnostic composition After administration of the radiodiagnostic composition to a test subject, an image is obtained to detect accumulated radioactivity and thus to determine the location thereof in the body tissue of the test subject.
- the radionuclide metal-containing complexes of the invention may be utilized in a number of different clinical and research imaging techniques, including without limitation, SPECT and PET.
- PET has been gaining increasing acceptance in the field of oncology.
- One of the principal advantages of positron imaging currently is its high detection efficiency and higher resolution, as compared to prior gamma- detectors. This technique is particularly well suited to the detection of tumor oxygen levels, providing results that are consistent with those obtained through invasive polarographic electrode measurements.
- Cu-64 is the preferred radionuclide for PET applications. It can be obtained from the Mallinckrodt Institute of Radiology, or may be prepared as described in U.S. Patent 6,001,825. PET imaging systems are available from commercial sources. See also, U.S. Patent 5,451,789 to Wong et al. ("High Performance Positron Camera").
- Examples 1-4 describe the synthesis and purification of representative cyclam derivatives of the invention, as well as the preparation of complexes of such derivatives with suitable ⁇ -emitting radionuclides. In the examples, all temperatures are given in degrees Centigrade, unless otherwise indicated.
- This material was dissolved in 300 ⁇ l of 1 N HCl.
- the flask was placed in a beaker containing 25 ml of abs. ethanol in a dessicator. After 2 days, a large portion of the white crystals was removed and the remaining crystals combined with the 190 mg fraction.
- the combined products were dissolved in 2 ml of water, the solution rendered basic with 3.0 ml of 1 N NaOH and extracted with 5 x 2 ml of methylene chloride. The solvent was evaporated from the combined extracts and the residue dried to give 184.6 mg of partially crystalline yellow material.
- This product was dissolved in 300 ⁇ L of abs. ethanol and applied to a 20 x 153 mm column of E. Merck silica gel 60 (230-400 mesh). The column was developed with: chloroform 175 ml; abs. ethanol 275 ml; cone. NH 4 OH 50 ml.
- Fractious 8-11 gave 60.5 mg of a yellow syrup from which a few needle-like crystals separated.
- This product was dissolved in 820 ⁇ L of 1 N HCl.
- the flask was placed in a beaker of abs. ethanol in a dessicator at atmospheric pressure for 4 days. At this time, there was a small area of crystaline material in the neck. There were numerous small globules of clear yellow liquid on the walls.
- the slightly cloudy mother liquor was transferred to another flask that was placed in a beaker of alcohol for 4 days. Cream colored crystals were deposited.
- the solution was passed through a 0.8 X 4 cm BioRad Poly-Prep Chromatography Column (cat #731-1550) containing 0.31 g BioRad Ag 1-X8 ion exchange resin, chloride form, 200-400 mesh (cat # 140-1451).
- the column was rinsed with 1.0 ml deareated distilled water. At this point, the radiolabeled ligand in the eluant was ready as a radiodiagnostic agent.
- the solution was allowed to incubate at room temperature for one- half hour.
- the solution was filtered through a 0.22 ⁇ filter, which renders it ready for use as a radiodiagnostic agent.
- Figure 2 shows two pairs of Fischer X Copenhagen rats in which R3327-AT and R3327-H tumors of approximately equal volume were growing and to which Ceretec®, radiolabeled with Tc-99m, and the complex of this example were administered i.v.. Ceretec® is a commercial tumor perfusion marker.
- Planar images using a collimated gamma camera were acquired six to seven hours after marker administration. After the imaging procedure, animals were sacrificed and the specific activity of hypoxic marker in blood, muscle and tumor tissue was measured. The tumor specific activity of these markers is presented in Example 5, below.
- Figure 4 shows the uptake of the radiodiagnostic complex of this example in a pair of Fischer X Copenhagen rats in which R3327-AT (Fig. 4A) and R3327-H (Fig. 4B) tumors of approximately equal volume were growing.
- the tumors of 8-10 gm. weight, are indicated by a black circle in each figure. Tumor specific activity was determined to be about 2.2.
- HSF - hypoxia-specific factor refers to the amount of marker bound to (or retained in) hypoxic cells relative to aerobic cells in vitro. See Chapman et al., Radiotherapy and Oncology, 46: 229-37 (1998) Km-concentration of O2 at which binding rate of marker is at 50% of maximum (normally defined in vitro)
- T/B-maximal tumor/blood ratio of tissue-specific radioactivity T/M-maximal tumor/muscle ratio of tissue-specific radioactivity %ID/g AT - percentage of injected dose of marker/g in anaplastic tumor tissue assessed 6 hours following injection. Specific activities were corrected to a standard rat weight of 400 g. Anaplastic tumors formed following injection of cells from the Dunning rat prostate carcinoma, R3327-AT.
- %ID/g H - percentage of injected dose of marker/g in well-differentiated tumor tissue assessed 6 hours following injection. Specific activities were corrected to a standard rat weight of 400 g.
- the radiodiagnostic agent of Example 4b was recovered from the hypoxic tumors at a level of about three times higher than the non-hypoxic, well oxygenated tumors. It is also noteworthy that up to six-fold higher levels were observed in individual pairs of animals.
- Tc-99m labelled Ceretec® distributed to the well oxygenated tumors at a level of about 1.7 times higher than hypoxia tumors.
- the following example describes PET imaging, using Cu-64- labelled cyclam derivatives of the present invention to detect and quantify tumor hypoxic microenvironments in prostate carcinomas of laboratory animal test subjects.
- a micro-PET imaging system using luetium oxyorthosilicate detector elements (Concord Microsystems, Knoxville, TN) with an 8-cm field of view, a spatial resolution of 2 mm at the center of the field of view and a volumetric resolution of about 8 ⁇ l may be used to image and quantitate rat tumor metabolism and viable hypoxic cells.
- the animals, bearing implanted hypoxic and non-hypoxic prostate carcinomas, are anesthetized with Avertin (Aldridge, Milwaukee, WI) before the imaging procedure.
- the long access of the rats is parallel to the long access of the scanner.
- each rat is injected i.v.
- each rat is reanesthesized and repositioned so as to acquire PET images from the tumor region.
- the rat is then injected with 2 mCi of optimal Cu-64-labelled cyclam derivative. Sequential scans are obtained from each rat using 5 minute aquisitions at 6 different times up to 8 hours after marker administration.
- Attenuation correction is determined with a 1 mCi Ge-68 ring transmission source and rat images are reconstructed using the 3-dimensional filtered back projection algorithm with the appropriate ramp filtered cutoff.
- Time activity curves are established for each organ in the field, including tumor, and the relative distribution of FDG and labelled cyclam derivative are determined.
- the standardized unit value (SUV) of metabolic activity and HF are calculated for each tumor at various times and statistical analysis of data are performed to assess differences in metabolism and hypoxic fraction of the two tumor types.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
1,4,8,11-Tetraazacyclotetradecane which is chemically linked to from one to four nitroimidazol groups provides an effective radiodiagnostic agent for determining tissue hypoxia and radioresistance of tumor tissue.
Description
1,4,8,11-TETRAAZACYCLOTETRADECANE DERIVATIVES AS
RADIODIAGNOSTIC AGENTS AND THEIR USE
IN DETERMINING HYPOXIA AND RADIORESISTANCE OF TUMORS
Pursuant to 35 U.S.C. §202(c), it is hereby acknowledged that the U.S. Government has certain rights in the invention described herein, which was made in part with funds from the National Institutes of Health (Grant No. CA 06927)
BACKGROUND OF THE INVENTION
This invention relates to derivatives of 1,4,8,11- tetraazacyclotetradecane (cyclam) which demonstrate hypoxic cell selectivity and retention and which are useful as radiodiagnostic agents for assessing tissue oxygenation status non-invasively, as well as to methods for preparing such derivatives and radionuclide metal-containing complexes thereof and their use for imaging and non-invasively determining tissue hypoxia and radioresi stance of tumors.
Hypoxic cells are known to exist in both animal and human tumors and this cell population has been shown to be 2.5 to 3 times more resistant than normally oxygenated cells to therapeutic radiation. The presence of these radioresistant populations in tumors presents a serious obstacle to the curative potential of clinical radiotherapy. Radiobiologic hypoxic fraction (HF), the fraction of clonogenic tumor cells that exhibit maximum radioresistance, has been shown to be an important parameter for predicting tumor treatment resistance and for the selection of aggressive and metastatic cell phenotypes. If this tumor property were known by clinicians at the time of diagnosis, it would be a useful predictor of tumor treatment response and would define subsets of patients for whom targeted therapies would produce improved cure rates. Thus,
radiodiagnostic agents that can accurately assess the presence and extent of hypoxic tissues in tumors would be of invaluable assistance in designing the appropriate therapeutic regimen and in following the response of tumor tissue to therapy. Although various agents and methods have been proposed for the detection and measurement of hypoxic cells in tumors, and direct pO2 measurements have been obtained from accessible tumors using microelectrodes, there is no practical, clinically useful diagnostic agent or method currently available. Some experimental procedures to assess tumor hypoxia are invasive, requiring multiple biopsy specimens that cannot always be obtained.
A promising approach to the assessment of hypoxic tissue is suggested by the ability of certain classes of compounds to selectively localize in these tissues after intravenous administration. The radiosensitizing drug, misonidazole (MISO), was shown to become selectively bound to the macromolecular fraction of EMT-6 murine tumor and V-79 hamster lung cells in hypoxic in vitro incubation studies (J.D. Chapman et al., Cancer Res., 43: 1523- 1528 (1983)) and to EMT-6 tumors in BALB/C mice (B.M. Garrecht et al., Brit. J. Radiol., 56: 745-753 (1983)). Selective binding of a γ-emitting analogue of a suitable compound would allow imaging and measurement of hypoxic tissue by conventional nuclear medicine techniques. Based on this approach, a number of analogues of 2-nitroimidazole have been investigated as potential non-invasive, hypoxic tissue specific, nuclear medicine imaging agents. The selective toxicity to hypoxic cells by 2-nitroimidazole has been shown to correlate with the accumulation of cellular reduction products of these compounds (J.D. Chapman, Cancer, 54: 2441-2449 (1984)).
The exact mechanism of the binding to the macromolecular fraction of cells remains under investigation, but is believed to rely on reduction of the nitroheterocycle through a series of one-electron transfers that produce nitroso, hydroxylamino and amino products (J.E. Biaglow et al., Biochem. Pharmacol, 35: 77-90 (1986)). This process is reliant on flavoproteins known as nitroreductases. The enzymes are functional only in viable cells and the
progression of the reduction past the one-electron stage (nitro radical anion) is strongly inhibited by oxygen, since this species can accept the electron from the nitro radical anion, thereby regenerating the nitroheterocycle. Further reductive metabolism and subsequent binding will, therefore, only be expected to take place in poorly oxygenated yet viable (hence hypoxic) cells.
A number of experimental hypoxic tissue imaging agents incorporating γ-emitting radionuclides have been investigated. These include 4- bromomisonidazole (D.C. Jette et al., Int. J. Nucl. Med. Biol, 10: 205-210 (1983); J.S. Rasey et al., Radiat. Rse., 91: 542-554 (1982)), l-(2-iodophenoxy)- ethyl)-2-nitroimidazole (L.I. Wiebe, Nucelarmedizine, 23: 63-67 (1984)), a series of iodinated acetophenone derivatives of 2-nitroimidazole (J.R. Mercer et al., J. Lab. Comp. Radiopharm., 25: 107-108 (1988)), fluoromisonidazole (F-MISO) (P.A. Jerabek et al., Appl. Radiat. hot, 37: 599-605 (1986)) the 2-nitroimidazole nucleoside analogue, iodoazomycin riboside (IAZR) (D.C. Jette et al., Radiat. Res., 105: 169-179 (1986); L.I. Wiebe et al., In Nuclear Medicine in Clinical
Oncology, Heidelberg, Springer- Verlag, pp. 402-407 (1986)) and certain azomycin nucleosides, namely iodoazomycin arabinoside (IAZA), iodoazomycin galactopyranoside (IAZGP) and iodoazomycin xylopyranoside (IAZXP), which are the subject of U.S. Patent 5,401,490. At millimolar concentrations, IAZGP and IAZA have been found to be selectively toxic to hypoxic EMT-6 tumor cells and also sensitize these cells to the lethal effects of ionizing radiation. At micromolar concentrations, IAZA is taken up preferentially in EMT-6 tumor tissue at a level useful for non-invasive imaging. An imaging study using 125I-IAZA showed EMT-6 tumor tissue to be clearly delineated from surrounding tissue. More recently, pilot clinical studies using 123I-IAZA with single photon emission computed tomography (SPECT) and 18F-FMISO with positron emission tomography (PET) have been reported. These data were recently reviewed and it appears unlikely that either marker is optimal for routinely determining the HF of individual human tumors (J.D. Chapman et al., Radiother. Oncol., 46: 229-37 (1998)). Among the azomycin-nucleoside markers, IAZXP and IAZGP have been shown to exhibit the most favorable
properties for marking the HF of solid rodent tumors in vivo (J.D. Chapman et al. (1988), supra).
Although the azomycin nucleosides, and particularly IAZGP, have been found to have useful hypoxic marking properties, an extensive research effort is ongoing to identify hypoxic markers which exhibit good bioavailability to all tissues, low lipophilicity to promote rapid renal excretion, are amenable to detection at optimal times after administration and can be convenientily labelled with the preferred nuclear medicine isotopes.
SUMMARY OF THE INVENTION
In accordance with one aspect of the present invention, cyclam derivatives are provided having the formula:
, wherein at least one of said R,, R2, R3 and R4 contains 2-nitro-imidazol- 1-yl moiety of the formula:
which is chemically linked to the cyclam nitrogen through any of various divalent linking groups. The remaining Rs are hydrogen. Preferably, the linking group comprises a chain of 2 to 7 atoms selected from the group of carbon or nitrogen, wherein the moiety
connecting the cyclam nitrogen and the 1-imidazole nitrogen to the remainder of the linking group is a -CH2- moiety, the carbons in the remainder of the linking moiety being optionally substituted with a hydroxyl group, and two adjacent carbons in the linking groups being optionally replaceable by an amide group. Stereoisomers, including both enantiomers, meso forms and diastereomers of the cyclam derivatives of the above general formula, as well as the pharmaceutically acceptable salts of such cyclam derivatives and their isomers, are included within the present invention.
The present invention also provides radiodiagnostic complexes comprising a cyclam derivative, as described above, and various complex- forming radionuclide metals.
According to a further aspect of the invention, a process is provided for preparation of the cyclam derivatives of the invention. Briefly, this method involves the nucleophilic displacement by cyclam of a suitable leaving group on a moiety containing azomycin.
According to yet another aspect, the present invention provides radiodiagnostic compositions comprising the above-mentioned radionuclide metal-containing complexes and a biologically compatible carrier medium for use in determining tumor hypoxia and radioresistance, as well as in imaging body tissue of a living test subject.
There is also provided, in accordance with this invention, a method of preparing a radionuclide metal-containing complex, as described above, by causing a salt or chelate of a radionuclide metal to undergo a complex- forming reaction with a cyclam derivative of the above formula, or a metal adduct thereof. A kit is also provided for carrying out such method. The kit contains
(i) a cyclam derivative, or a metal adduct thereof, and (ii) instructions for reacting the cyclam derivative or metal adduct thereof, with a radionuclide metal selected from the group of the radioactive isotopes of Tc, Cu, Ru, Co, Pt, Fe, Os, Ir, W, Re, Cr, Mo, Mn, Ni, Rh, Pd, Nb, Pb, Ga, As, In and Ta to produce the complex. According to yet a further aspect of the invention, a novel non- invasive method is provided for the detection and measurement of tissue hypoxia
in a mammal comprising the steps of:
(a) administering a radiodiagnostic complex, as described above, such that that complex is taken up selectively and retained by the hypoxic tissue; and (b) quantifying the extent of retained complex by the γ- emission from said complex.
According to still a further aspect of this invention, there is provided a method for imaging body tissue of a living test subject by administering to the test subject a radionuclide metal-containing complex, as described herein, and detecting the localization of the complex in the body tissue using a suitable radiation detector. Of course, different detectors may be employed depending on the nature of the emission produced by the radioactive metal present in the complex. Suitable detectors include, without limitation, SPECT and PET cameras. The cyclam derivatives of the present invention are considered superior to previously reported radiodiagnostic agents for measuring hypoxia and predicting tumor radioresistance because of their high specific activity and the large differential labelling of experimental tumors having a an HF of 15-20%, as compared to tumor tissue that exhibits no detectable HF. Furthermore, in that radiation resistance and some chemotherapeutic drug resistance correlate with tumor hypoxia, the ability to define one type of tumor resistance in advance of therapy is important, since various modalities of targeted cancer treatment, such as chemical radiosensitizers, chemopotentiation agents and bioreductive drugs, can now be directed towards treatment-resistant hypoxic cells.
In addition, a radiodiagnostic agent for oxygenation status will be useful in detecting and defining other disease states, including myocardial infarct and cerebrovascular hemorrhage, in which ischemia and/or infarct play a role and in infections which involve anaerobic foci.
BRIEF DESCRIPTION OF THE DRAWINGS
The file of this patent contains at least one drawing executed in color. Copies of this patent with color drawing(s) will be provided by the Patent and Trademark Office upon payment of the necessary fee. FIGURE 1 is a graphical representation of typical marker biodistribution data obtained by measuring percentage of injected dose of marker/gram of assessed tissue (% ID/G) as a function of time for eight different tissues from five EMT6 tumor-bearing scid mice, up to 10 hours after intravenous
(i.v.) administration of a Tc-99m containing mono-[2-hydroxy-3-(2- nitroimidazol- l-yl)propyl-substituted cyclam complex. The eight tissues evaluated are represented as follows: • = blood; ■ = liver; Δ = kidney; v = spleen; ♦ = lungs; = muscle; O = brain; D = tumor.
FIGURES 2A-D show collimated, gamma-camera planar images of two pair of R 3327-AT (left; hypoxic) and R 3327-H (right; non-hypoxic) tumor-bearing rats six hours after i.v. administration of Tc-99m-labelled
Ceretec® (Figures 2A and 2B) and a Cu-67-containing tetra-[2-hydroxy-3-(2- nitroimidazol-l-yl)-propyl] -substituted cyclam (Figures 2C and 2D). The tumor site is indicated by an arrow in each image.
FIGURE 3 is a graphical representation of data showing the binding rate (dpm/106 cells/hr) of a Cu-64 containing tetra-[2-hydroxy-3-(2- nitroimidazol-l-yl)propyl]-substituted cyclam to tumor cells in vitro, as a function of oxygen concentration.
FIGURES 4A and B show collimated, gamma camera planar images of a pair of R3327-AT (left; hypoxic) and R3327-H (right; non-hypoxic) tumor bearing rats 5-7 hours after administration of a Cu-64 containing tetra-[2- hydroxy-3-(2-nitroimidazol-l-yl)propyl]-substituted cyclam.
DETAILED DESCRIPTION OF THE INVENTION
The cyclam derivatives of formula I, above, can be prepared from known starting materials and the syntheses of specific embodiments of such derivatives that are within the scope of the invention are exemplified below.
Certain of these derivatives have been used for radiodiagnostic imaging of animal tumor models and for evaluating their ability to determine tissue hypoxia and assess their hypoxic marking properties, as reported below.
Suitable linking groups for linking the 2-nitro-imidazolyl moiety to the cyclam nucleus are those of the formula
-(CHRa)n-X-(CHRb)m-Y-(CHRc)p-, wherein Ra and Rc represent hydrogen or alkyl (CrC4) and Rb represents hydrogen, alkyl ( -C , hydroxyl, X and Y may be the same or different and represent a structural group, such as an amide (-C(=O)NH-), urea (-NH-C(=O)-NH-), thiourea (-NH-C(=S)-NH-), carbamic (-NH-C(=O)-O-), amine (-NH-), carbonyl (-C(=O)-), and amidine
(-NH-C=(NHe)-); disulfide (-S-S-), ether (-O-), thioether (-S-) or sulfonamide (-S(=O)2-NH-) group, n is an integer from 1 to 6, m is an integer from 1 to 6 and p is an integer from 1 to 6.
Preferably, at least one of the cyclam ring nitrogens is linked to a nitroimidazolyl moiety of the above formula through an unsubstituted or hydroxyl-substituted divalent alkylene linking moiety of 2 to 7 carbon atoms, which may optionally be interrupted by at least one group containing the amide moiety. Representative examples of suitable linking moieties include -CH2- CH(OH)-CH2-; -(CH2)2-NH-C(=O)-CH2-; -CH2-C(=O)-NH-(CH2)2-; (CH2)2-C(=O)-NH-(CH2)3-; -(CH2)3-.
Particularly preferred embodiments of the present invention are the mono-, di- and tetra-2-nitroimidazol-l-yl-substituted cyclam derivatives in which the nitroimidazolyl moiety is linked to the ring nitrogen of cyclam via a linkage having the structure -CH2-CH(OH)-CH2-. These particular derivatives have an asymmetric center in the linking moiety. This makes the mono- substituted compound resolvable into a pair of optical isomers. On the other hand, the di- and tetra-substituted derivatives are separable into d, 1 (racemic) and meso forms, which contain a plane of symmetry and, therefore, are resolvable into optical isomers. The cyclam derivatives of this invention can form soluble salts with pharmaceutically acceptable acids, such as hydrochloric, phosphoric, tartaric
and citric acids, and these salts are also within the scope of the present invention. The pharmaceutically acceptable salts of the cyclam derivatives described herein can be prepared following procedures that are familiar to those skilled in the art. The cyclam derivatives described herein form a complex with various radionuclide metals selected from the group of the radioactive isotopes of
Tc, Cu, Ru, Co, Pt, Fe, Os, Ir, W, Re, Cr, Mo, Mn, Ni, Rh, Pd, Nb, Pb, Ga, As, In and Ta, for example, Tc-99m, Cu-67, Cu-64, Cu-62, Pb-203, Ga-67, Ga-68, As- 72, In-I l l, In-113m, Ru-97, Fe-52, Mn-52m, Cn-51 and Co-57. Particularly preferred complex -forming radionuclide metals for use in the present invention are Tc-99m, Cu-67, Cu-64 and In-111. The complexes have a net positive charge and are associated with counter anions, which may be BF4-, ClO4-, Br-, CF3COO-, C1-, or the like, depending on the manner in which they are prepared.
The radionuclide metal-containing complexes, as described above, are prepared by causing a salt or chelate of a suitable radionuclide metal to undergo a complex-forming reaction with a cyclam derivative of the invention.
Complex formation is effected by contacting the cyclam derivative with the desired metal in the form of a salt or in the form of a chelate wherein the metal is bound to a relatively weak chelator. In using a metal chelate as starting material for the complex formation, the desired complex is formed via the principle of ligand exchange.
A reducing agent may be required for the above reaction, as in cases where technetium metal is used. Suitable reducing agents for this purpose include Sn(LI) compounds, dithionites, sodium borohydride, and the like.
Given the relatively short half-life of the radionuclide metal used in the practice of this invention, it is frequently impossible to put the ready-for- use complexes at the disposal of those wanting to use them. In such cases, the user will carry out the labeling reaction with the radionuclide in the clinical or laboratory setting. To that end, the various reaction components may be conveniently provided in kit form. Because the radiodiagnostic composition of the present invention can be prepared in a sample manner, this process may be readily carried out by experienced researches or clinicians. Such a kit will
typically contain (i) a cyclam derivative of the general formula I, shown above, to which an inert biologically acceptable carrier medium and/or formulating agent(s), e.g., reducing agent(s), and/or auxiliary substance(s) may optionally be added, and (ii) instructions for carrying out a complex-forming reaction using the components present in the kit. As mentioned above, for such complex-forming reaction the desired radionuclide may be contacted with cyclam derivative in the form of a chelate, bound to a relatively weak chelator, such as a glucoheptonate, pyrophosphate, a polyphosphate, a phosphonate or polyphosphonate, an oxinate, a carboxylate, a hydroxycarboxylate, an aminocarboxylate, an enolate or a mixture thereof, such reaction being carried out under moderate conditions.
The kit embodiment of this invention may optionally comprise a solution of the radionuclide metal. Because such solutions have a limited shelf life, however, they may be made available separately.
The components of the above-described kit may be supplied as a solution, for example, in the form of a physiological saline solution, or in a buffer solution. If desired, the above-mentioned components may be stabilized in a usual way with suitable stabilizers such as ascorbic acid, gentisic acid or salts of these acids.
Radiodiagnostic compositions comprising a radionuclide metal- containing complex, as described above, may be conveniently formulated for administration with a biologically acceptable carrier medium. According to a preferred embodiment, the carrier medium is sterile, pyrogen-free phosphate buffered sale (PBS). The radiodiagnostic agents of the invention should be delivered to tissue in trace amounts, on the order of 10"12M. Nuclear medicine markers are usually administered according to their biodistribution, with isotope dose up to 40 mCi in the case of Tc-99m, for example. In all cases, any substance used in formulating a radiodiagnostic composition in accordance with this invention should be virus-free, pharmaceutically pure and substantially non- toxic in the amount used. If necessary or desirable, the risk of contaminating microorganisms may be prevented by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, surbic acid, thimerosal or the like. It
may also be beneficial to include in the formulation isotonic agents such as glucose.
As used herein, the term "biologically acceptable carrier medium" is intended to include any and all solvents, dispersion media and the like which may be appropriate for the desired route of administration of the composition.
The use of such media for hypoxic markers is known in the art. Except insofar as any conventional carrier medium is incompatible with the particular radiodiagnostic agents described herein, its use in the compositions of the invention is contemplated. The radiodiagnostic agents of the invention are administered parenterally, intravenous administration being the preferred route.
After administration of the radiodiagnostic composition to a test subject, an image is obtained to detect accumulated radioactivity and thus to determine the location thereof in the body tissue of the test subject. The radionuclide metal-containing complexes of the invention may be utilized in a number of different clinical and research imaging techniques, including without limitation, SPECT and PET.
PET has been gaining increasing acceptance in the field of oncology. One of the principal advantages of positron imaging currently is its high detection efficiency and higher resolution, as compared to prior gamma- detectors. This technique is particularly well suited to the detection of tumor oxygen levels, providing results that are consistent with those obtained through invasive polarographic electrode measurements.
Cu-64 is the preferred radionuclide for PET applications. It can be obtained from the Mallinckrodt Institute of Radiology, or may be prepared as described in U.S. Patent 6,001,825. PET imaging systems are available from commercial sources. See also, U.S. Patent 5,451,789 to Wong et al. ("High Performance Positron Camera").
The following examples are provided to describe the invention in futher detail. These examples, which set forth the best mode presently contemplated for carrying out the invention, are intended to illustrate and to not
limit the invention. Examples 1-4 describe the synthesis and purification of representative cyclam derivatives of the invention, as well as the preparation of complexes of such derivatives with suitable γ-emitting radionuclides. In the examples, all temperatures are given in degrees Centigrade, unless otherwise indicated.
EXAMPLE 1
Preparation of mono-[2-hydroxy-3-(2-nitroimidazoI-l-yI) propylj-substituted cyclam 1,4,8,11-Tetraazacyclotetradecane (98%), 1.88 g (9.4 mmol) was dissolved in 12 ml of methanol. A solution of l-(2,3-epoxypropyl)-2- nitroimidazole, 366.8 mg (2.17 mmol) in 3.0 ml of methanol, was added dropwise to the cyclam solution with stirring. After 20 minutes at 25°, a trace of white solid appeared. The flask was wrapped in aluminum foil and allowed to stand five days.
Thin-layer chromatography (TLC) on an E. Merck silica gel 60F plate, developed in chloroform 3: abs. ethanol 6: cone. NH4OH 1, showed no evidence of the starting epoxide. A 5.00 ml aliquot of the reaction mixture was evaporated on a film evaporator and the residue dried over CaCl2 in vacuo. The solid was refluxed with 10 ml of methylene chloride for 35 minutes and the insoluble material separated by filtration. The clear yellow solution was evaporated to give 0.4393 g of residue that was dissolved in 1.0 ml of abs ethanol and applied to a 30 x 153 mm column of E. Merck silica gel 60 (230-400 mesh). The column was developed with a mixture of chloroform 400 ml; abs. ethanol 500 ml; and cone. NH4OH 100 ml; 20 ml fractions collected.
Fractions 7-14 gave a clear yellow oil that was dissolved in 4.0 ml of 1 N HCl. The flask was placed in an evacuated desiccator over CaCl2. After 4 days, some small white floes were removed from the yellow solution by filtration through sintered glass and the filtrate concentrated in a stream of N2 at 60°. The flask was placed in a beaker with 25 ml of abs. ethanol; the whole placed in a dessicator. After 7 days, the product consisted of a conical mass of pale yellow
crystal at the bottom of the flask and large clusters of fine white crystals over the surface of the liquid and on the upper walls of the flask. After removing the supernatant and drying overnight over CaCl2 in vacuo, the types of crystals were separated mechanically. The yellow crystals weighed 190.1 mg. A mixture of white and yellow crystals that could not be readily separated weighed 86.1 mg.
This material was dissolved in 300 μl of 1 N HCl. The flask was placed in a beaker containing 25 ml of abs. ethanol in a dessicator. After 2 days, a large portion of the white crystals was removed and the remaining crystals combined with the 190 mg fraction. The combined products were dissolved in 2 ml of water, the solution rendered basic with 3.0 ml of 1 N NaOH and extracted with 5 x 2 ml of methylene chloride. The solvent was evaporated from the combined extracts and the residue dried to give 184.6 mg of partially crystalline yellow material. This product was dissolved in 300 μL of abs. ethanol and applied to a 20 x 153 mm column of E. Merck silica gel 60 (230-400 mesh). The column was developed with: chloroform 175 ml; abs. ethanol 275 ml; cone. NH4OH 50 ml.
Fractions (10 ml) 7-19 were collected, concentrated and the oily yellow residue dissolved in methanol. This solution was filtered through a 0.45 μ PTFE syringe filter and the methanol evaporated. The residue was dried over CaCl2 in vacuo. This product weighed 114 mg. TLC showed two slow moving components. This material was rechromatographed in the same flash chromatography system.
Fractious 8-11 gave 60.5 mg of a yellow syrup from which a few needle-like crystals separated. This product was dissolved in 820 μL of 1 N HCl. The flask was placed in a beaker of abs. ethanol in a dessicator at atmospheric pressure for 4 days. At this time, there was a small area of crystaline material in the neck. There were numerous small globules of clear yellow liquid on the walls. The slightly cloudy mother liquor was transferred to another flask that was placed in a beaker of alcohol for 4 days. Cream colored crystals were deposited. After drying over CaCl2 followed by P2O5 in vacuo, this product, the tetrahydrochloride of l-[2-hydroxy-3-(2-nitroimidazol-l-yl)propyl]-,l,4,8,l 1- tetraazacyclotetradecane weighed 44.1 mg.
Electrospray mass spectrometry gave (M+l) = 370.2; calculated
value 370.
EXAMPLE 2 Di-[2-hydroxy-3-(2-nitroimadazol-l-yl)- propylj-substituted cyclam
Fractions 3 and 4 from the first column chromatography in the preparation of the mono-substituted compound (Example 1) gave 16.6 mg of material that was dissolved in 200 μL of 1 N HCl. The flask was placed in a beaker with abs. ethanol and kept in a dessicator at atmospheric pressure for 21 days. The yield of small bright yellow crystals was 12.5 mg.
A small portion was converted to the base, extracted into chloroform and subjected to TLC in the system described in Example 1. A major component of Rf 0.36 was by far the largest and most intense. Smaller spots were seen at Rf 0.44, 0.54 and 0.68. In another experiment, a very small amount of a bright yellow crystalline salt was obtained that on electrospray mass spectrometry gave (M+l) = 539.4. Calculated value 539.
EXAMPLE 3 Tetra-[2-hydroxy-3-(2-nitroimidazoI-l-yl)- propylj-substituted cyclam l-(2,3-Epoxypropyl)-2-nitroimidazole, 152.3 mg (0.900 mmol) was dissolved in 500 μL of acetonitrile. 1,4,8,11-Tetraazacyclotetradecane, 41.0 mg (0.205 mmol) was added, followed by 100 μL of acetonitrile and 10 μL of water. The cyclam did not dissolve. Methanol, 300 μL, was added and the mixture stirred at 32°. All but a trace of the cyclam dissolved. After standing 2 days, the thick slurry, containing a light yellow, very finely divided solid, was heated to 56-61° with stirring under reflux for 2-1/4 hours. Methanol, 500 μL, was added after the first hour. After standing 3 weeks, the solvent was removed in a stream of N2 while heating in a bath at 55°. The residue was broken up under 3.0 ml of
tetrahydrofuran. Di-tert-Butyl dicarbonate (99%) 301.5 mg, dissolved in 1.0 ml of tetrahydrofuran was added and the mixture stirred at room temperature for 4 days. The finely divided pale yellow solid was collected and dried overnight. This solid weighed 92.9 mg. It was stirred with 1.5 ml of 1.0 N HCl. The material that did not dissolve was stirred with 1.5 ml of cold trifluoroacetic acid.
On warming to 25°, a clear solution resulted. After filtration to remove a few white crystals, the bulk of the trifluoroacetic acid was evaporated in a stream of N2 and the residue dried over NaOH pellets in vacuo. The clear light yellow glass was dissolved in 1.00 ml of water and passed over a cation exchange column (9 mm dia x 11 mm long) containing 3.0 ml of IR-120 (plus) resin (capacity 1.9 meq/ml). Water, 4.0 mL was used as chaser. The effluent turned cloudy and a fine white precipitate separated. The solution was stirred while 6.0 N HCl was added dropwise until it was clear. After standing overnight, small pale yellow crystals of the tetrahydrochloride salt had deposited on the walls of the flask. These were collected and dried over CaCl2 in a vacuum dessicator.
Electrospray mass spectrometry gave (M+l)= 877. Calculated value 877.
EXAMPLE 4 Radiolabelling of Cyclam Derivatives a) N-[2-hydroxy)-3-(2-nitroimidazole-l-yl)propyl]-l,4,8,l 1- tetraazacyclotetradecanato-technetium V.
Into an 4 ml screw-cap vial were placed: 3.0 mg (5.8157 x 10"6 moles) cyclam derivative prepared in Example 1, above; 3.0 ml deareated distilled water; 0.332 ml deareated 0.1 N sodium hydroxide solution; 0.2 ml
(13.55 mCl) NH4TcO4 generator eluate; and 20 μl saturated stannous tartarate solution prepared fresh using deareated distilled water. The mixture was incubated at room temperature for 0.5 hr.
The solution was passed through a 0.8 X 4 cm BioRad Poly-Prep Chromatography Column (cat #731-1550) containing 0.31 g BioRad Ag 1-X8 ion exchange resin, chloride form, 200-400 mesh (cat # 140-1451). The column was
rinsed with 1.0 ml deareated distilled water. At this point, the radiolabeled ligand in the eluant was ready as a radiodiagnostic agent.
The relative levels of Tc-99m delivered using the complex of this example in animal tissues, as shown in Figure 1, did not change significantly over the first ten hours after administration. [Add explanation of symbols in Fig. 1]. b) N, N', N", N'"-Tetra[(2-hydroxy)-3-(2-nitroimidazole-l- yl) propyl]- 1,4,8,11-tetraazacyclotetradecanato-copper U.
To the 10 ml serum vials (each of which contained 5.1 m Cu 67CuCl2 in 0.240 ml 0.1 N HCl) were added: 3.00 ml distilled water; 3.8 mg (3.7155 x 10"6 moles) of the cyclam derivative prepared in Example 3, above; and
0.240 ml 0.1 N sodium hydroxide solution. The pH was determined and adjusted to 7.52 with additional IN or 0.1 N sodium hydroxide solution as required.
The solution was allowed to incubate at room temperature for one- half hour. The solution was filtered through a 0.22 μ filter, which renders it ready for use as a radiodiagnostic agent.
Figure 2 shows two pairs of Fischer X Copenhagen rats in which R3327-AT and R3327-H tumors of approximately equal volume were growing and to which Ceretec®, radiolabeled with Tc-99m, and the complex of this example were administered i.v.. Ceretec® is a commercial tumor perfusion marker. Planar images using a collimated gamma camera were acquired six to seven hours after marker administration. After the imaging procedure, animals were sacrificed and the specific activity of hypoxic marker in blood, muscle and tumor tissue was measured. The tumor specific activity of these markers is presented in Example 5, below. c.) A Cu-64-containing N, N', N", N'"-tetra(2-hydroxy)-3-(2- nitroimidazole-l-yl)propyl]-substituted cyclam was prepared following the same general procedure described in Example 4b, above.
The absolute binding rate of this radiodiagnostic complex to DU- 145 prostate cancer cells (ATCC) in vitro, as a function of oxygen concentration is shown in Figure 3. In this experiment, background binding to aerobic cells
(21% O2) was observed, which was probably due to ionic trapping of isotope on the filters.
Figure 4 shows the uptake of the radiodiagnostic complex of this example in a pair of Fischer X Copenhagen rats in which R3327-AT (Fig. 4A) and R3327-H (Fig. 4B) tumors of approximately equal volume were growing. The tumors, of 8-10 gm. weight, are indicated by a black circle in each figure. Tumor specific activity was determined to be about 2.2.
EXAMPLE 5
The following table sets forth data concerning hypoxic marking properties of radiolabelled cyclam derivatives of Examples 1 and 3, above.
HSF - hypoxia-specific factor refers to the amount of marker bound to (or retained in) hypoxic cells relative to aerobic cells in vitro. See Chapman et al., Radiotherapy and Oncology, 46: 229-37 (1998) Km-concentration of O2 at which binding rate of marker is at 50% of maximum (normally defined in vitro)
T/B-maximal tumor/blood ratio of tissue-specific radioactivity T/M-maximal tumor/muscle ratio of tissue-specific radioactivity %ID/g AT - percentage of injected dose of marker/g in anaplastic tumor tissue assessed 6 hours following injection. Specific activities were corrected to a standard rat weight of 400 g. Anaplastic tumors formed
following injection of cells from the Dunning rat prostate carcinoma, R3327-AT.
%ID/g H - percentage of injected dose of marker/g in well-differentiated tumor tissue assessed 6 hours following injection. Specific activities were corrected to a standard rat weight of 400 g. Well-differentiated tumors formed following injection of cells from the Dunning rat prostate carcinoma, R3327-H. e AT/H - ratio of specific activities in anaplastic (hypoxic) versus well- differentiated (non-hypoxic) tumor tissues.
ND = Not determined
As the data show in the above table, the radiodiagnostic agent of Example 4b, above, was recovered from the hypoxic tumors at a level of about three times higher than the non-hypoxic, well oxygenated tumors. It is also noteworthy that up to six-fold higher levels were observed in individual pairs of animals. By comparison, Tc-99m labelled Ceretec® distributed to the well oxygenated tumors at a level of about 1.7 times higher than hypoxia tumors. In this connection, see Moore et al., Brit. J. Cancer, 65: 491-97 (1992). The following example describes PET imaging, using Cu-64- labelled cyclam derivatives of the present invention to detect and quantify tumor hypoxic microenvironments in prostate carcinomas of laboratory animal test subjects.
EXAMPLE 6
A micro-PET imaging system using luetium oxyorthosilicate detector elements (Concord Microsystems, Knoxville, TN) with an 8-cm field of view, a spatial resolution of 2 mm at the center of the field of view and a volumetric resolution of about 8 μl may be used to image and quantitate rat tumor metabolism and viable hypoxic cells. The animals, bearing implanted hypoxic and non-hypoxic prostate carcinomas, are anesthetized with Avertin (Aldridge,
Milwaukee, WI) before the imaging procedure. The long access of the rats is parallel to the long access of the scanner. On the day of the procedure, each rat is injected i.v. with 2 mCi of labelled fluorodeoxyglucose (18FDG) (1.0-1.5 ml) followed by a line flush with 500 μl of physiological saline. Three sequential whole body studies are performed on each rat using 5 minute acquisitions for each bed position, between 3-8, depending on the rat length. The following day, each rat is reanesthesized and repositioned so as to acquire PET images from the tumor region. The rat is then injected with 2 mCi of optimal Cu-64-labelled cyclam derivative. Sequential scans are obtained from each rat using 5 minute aquisitions at 6 different times up to 8 hours after marker administration.
Attenuation correction is determined with a 1 mCi Ge-68 ring transmission source and rat images are reconstructed using the 3-dimensional filtered back projection algorithm with the appropriate ramp filtered cutoff. Time activity curves are established for each organ in the field, including tumor, and the relative distribution of FDG and labelled cyclam derivative are determined. The standardized unit value (SUV) of metabolic activity and HF are calculated for each tumor at various times and statistical analysis of data are performed to assess differences in metabolism and hypoxic fraction of the two tumor types. Although the present invention has been described and exemplified in terms of certain preferred embodiments, other embodiments will be apparent to those skilled in the art. The invention is, therefore, not limited to the particular embodiments described and exemplified, but is capable of modification or variation without departing from the spirit of the invention, the full scope of which is delineated by the appended claims.
Claims
1. A derivative of 1,4,8,11-tetraazacyclotetradecane (cyclam), said derivative having the formula:
, wherein at least one of said R,, R2, R3 and R4 contains a 2-nitroimidazol- 1-yl moiety of the formula:
each said 2-nitroimidazolyl moiety being linked to a cyclam ring nitrogen through a linking group, any remaining R,, R2, R3 and R4 radicals representing hydrogen, and the stereoisomers and pharmaceutically acceptable salts of said derivative.
2. A cyclam derivative as claimed in claim 1, wherein said linking group comprises a chain of 2 to 7 atoms selected from the group of carbon or nitrogen, wherein the moiety connecting the cyclam nitrogen and the 1- imidazole nitrogen to the remainder of said linking group is a -CH2- moiety, the carbons in the remainder of said linking moiety being optionally substituted with a hydroxyl group, and two adjacent carbons in said linking groups being optionally replaceable by an amide group.
3. A cyclam derivative as claimed in claim 1, wherein said linking group is selected from those consisting of
-CH2- CH(OH)-CH2-; -(CH2)2-NH-C(=O)-CH2-; -CH2-C(=O)-NH-(CH2)2-; - (CH2)2-C(=O)-NH-(CH2)3; -(CH2)3-.
4. A cyclam derivative as claimed in claim 3, wherein R[ is a
2-nitroimidazolyl group and R2, R3 and R4 represent hydrogen.
5. A cyclam derivative as claimed in claim 3, wherein two of said R,, R2, R3 and R4 represent 2-nitroimidazolyl, and the other two of said R,, R2, R3 and R4 represent hydrogen and said linking moiety is -CH2-CH(OH)-CH2-.
6. A cyclam derivative as claimed in claim 3, wherein each of said R,, R2, R3 and R4 groups represents 2-nitroimidazolyl and said linking moiety is -CH2-CH(OH)-CH2-.
7. A radionuclide metal complex comprising a cyclam derivative, as claimed in claim 1, and a γ ray-emitting radionuclide.
8. A complex as claimed in claim 7, wherein said γ ray- emitting radionuclide is selected from the group consisting of Tc-99m, Cu-67 and
In-111.
9. A radionuclide metal-containing complex comprising a cyclam derivative as claimed in claim 1 and a radionuclide metal selected from the group of the radioactive isotopes of Tc, Cu, Ru, Co, Pt, Fe, Os, Ir, W, Re, Cr,
Mo, Mn, Ni, Rh, Pd, Nb, Pb, Ga, As, In and Ta.
10. A method of identifying hypoxic tissue in a living test subject, said method comprising the steps of
(a) administering to said test subject a complex, as claimed in claim 9, such that said complex is taken up selectively and retained by said hypoxic tissue; and
(b) quantifying the radiation emitted from said complex.
11. A method as claimed in claim 10, wherein said complex is formed with a γ ray-emitting radionuclide selected from the group consisting of
Tc-99m, Cu-67 and In-111
12. A method as claimed in claim 10, wherein said complex is administered intravenously.
13. A method as claimed in claim 10, wherein said hypoxic tissue is a component of tumor tissue.
14. A method as claimed in claim 10, wherein said hypoxic tissue is ischaemic heart tissue.
15. A method as claimed in claim 10, wherein said hypoxic tissue is ischaemic brain tissue.
16. A radiodiagnostic composition comprising a complex as claimed in claim 9 and a biologically acceptable carrier medium.
17. A method of preparing a radionuclide metal-containing complex as claimed in claim 9, wherein a salt or chelate of said radionuclide metal is caused to undergo a complex-forming reaction with said cyclam derivative.
18. A kit for preparing a radionuclide metal-containing complex containing (i) a cyclam derivative as claimed in claim 1, or a metal adduct thereof, and (ii) instructions for reacting said cyclam derivative with a radionuclide metal selected from the group of the radioactive isotopes of Tc, Cu,
I Ru, Co, Pt, Fe, Os, Ir, W, Re, Cr, Mo, Mn, Ni, Rh, Pd, Nb, Pb, Ga, As, In and Ta to produce said complex.
19. A kit as claimed in claim 18, which further contains a solution of a salt or chelate of said radionuclide metal.
20. A method for imaging body tissue of a living test subject comprising administering to said test subject a radionuclide metal-containing complex as claimed in claim 9, and detecting the localization of said complex in said body tissue by a radiation detector.
21. A method for imaging body tissue as claimed in claim 20, wherein said complex contains a radionuclide metal selected from the group of Tc-99m and Cu-67, and said detector is a gamma detector.
22. A method for imaging body tissue as claimed in claim 20, wherein said complex contains Cu-64 as said radionuclide metal, and said detector is a positron detector.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11725399P | 1999-01-26 | 1999-01-26 | |
US117253P | 1999-01-26 | ||
PCT/US2000/001754 WO2000043004A1 (en) | 1999-01-26 | 2000-01-26 | 1,4,8,11-tetraazacyclotetradecane derivatives as radiodiganostic agents and their use in determining hypoxia and radioresistance of tumors |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1148878A1 true EP1148878A1 (en) | 2001-10-31 |
EP1148878A4 EP1148878A4 (en) | 2003-04-02 |
Family
ID=22371814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00908353A Withdrawn EP1148878A4 (en) | 1999-01-26 | 2000-01-26 | 1,4,8,11-tetraazacyclotetradecane derivatives as radiodiganostic agents and their use in determining hypoxia and radioresistance of tumors |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1148878A4 (en) |
CA (1) | CA2361115A1 (en) |
WO (1) | WO2000043004A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2420645A1 (en) | 2000-09-25 | 2002-04-04 | The Procter & Gamble Company | Metal complexes for use in medical and therapeutic applications |
WO2005087275A2 (en) * | 2004-03-11 | 2005-09-22 | Board Of Regents, The University Of Texas System | Metal radiolabeled pet imaging agents |
US7842278B2 (en) * | 2006-10-27 | 2010-11-30 | Natural Pharmacia International, Inc. | Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof |
US9408928B2 (en) | 2007-03-27 | 2016-08-09 | Radiomedix, Inc. | Compositions for targeted imaging and therapy |
CN101486708B (en) * | 2009-02-27 | 2012-08-29 | 北京师范大学 | 4-nitro glyoxaline compound, preparation and use thereof |
CN101486707B (en) * | 2009-02-27 | 2012-08-29 | 北京师范大学 | 2-methyl-5-nitro glyoxaline compound, preparation and use thereof |
US9233971B2 (en) * | 2010-08-26 | 2016-01-12 | Kunyuan Cui | Lipomacrocycles and uses thereof |
DK2721045T3 (en) | 2011-06-20 | 2017-07-24 | Radiomedix Inc | COMPOSITIONS, METHODS OF SYNTHESIS AND USE OF CARBOHYDRATE TARGETED AGENTS |
WO2019056097A1 (en) * | 2017-09-19 | 2019-03-28 | The Governors Of The University Of Alberta | Markers, conjugates, compositions and methods for hypoxia imaging, mapping, and therapy |
CA3076259A1 (en) * | 2017-09-19 | 2019-03-28 | The Governors Of The University Of Alberta | Bioreductively-activated compounds, their prodrugs, radiopharmaceuticals, the compositions, and their applications in multimodal theranostic management of hypoxia diseases including cancer |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2654102B1 (en) * | 1989-11-09 | 1992-01-10 | Air Liquide | PROCESS FOR THE SYNTHESIS OF CYCLIC POLYAZOT DERIVATIVES. |
JP2885944B2 (en) * | 1991-02-01 | 1999-04-26 | 富士写真フイルム株式会社 | Amine compound having heterocyclic group |
US5708022A (en) * | 1994-10-28 | 1998-01-13 | Procept, Inc. | Method for inhibiting immune response |
GB9511357D0 (en) * | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
-
2000
- 2000-01-26 CA CA002361115A patent/CA2361115A1/en not_active Abandoned
- 2000-01-26 WO PCT/US2000/001754 patent/WO2000043004A1/en not_active Application Discontinuation
- 2000-01-26 EP EP00908353A patent/EP1148878A4/en not_active Withdrawn
Non-Patent Citations (2)
Title |
---|
No further relevant documents disclosed * |
See also references of WO0043004A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2361115A1 (en) | 2000-07-27 |
EP1148878A4 (en) | 2003-04-02 |
WO2000043004A1 (en) | 2000-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2079486B1 (en) | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications | |
Hoigebazar et al. | Synthesis and characterization of nitroimidazole derivatives for 68Ga-labeling and testing in tumor xenografted mice | |
CA2649869C (en) | Compositions and methods for cellular imaging and therapy | |
EP3206720B1 (en) | Conjugated bisphosphonates for the diagnosis and therapy of bone diseases | |
JPH075527B2 (en) | Bifunctional DTPA type ligand | |
WO2005087275A2 (en) | Metal radiolabeled pet imaging agents | |
US20080124273A1 (en) | Novel cationic metal complex radiopharmaceuticals | |
EP1148878A1 (en) | 1,4,8,11-tetraazacyclotetradecane derivatives as radiodiganostic agents and their use in determining hypoxia and radioresistance of tumors | |
WO1993019787A1 (en) | Radiopharmaceuticals for imaging the heart | |
EP1192166B1 (en) | Group(vii) transition-metal complexes with multidentate aminopolycarboxylate ligands and a kit for producing them | |
JPH06100519A (en) | Chelate compound, its metal complex, diagnostic agent and medicine containing same for treatment of tumor and preparation of chelate compound | |
Sadeghzadeh et al. | Synthesis, radiolabeling and biological evaluation of 99mTc-labeled deoxyglucose derivatives for molecular imaging | |
KR100430061B1 (en) | Radioisotope labeled complex of glucose derivatives and kit for preparation thereof | |
US4622217A (en) | I-4-amino-3-iodobenzylguanidine as imaging and therapeutic agent | |
US6926883B1 (en) | Group (VII) transition-metal complexes with multidentate aminopolycarboxylate ligands and a kit for producing them | |
DE19860289A1 (en) | New chelators and their tricarbonyl complexes with technetium and rhenium | |
US8846001B2 (en) | Labelled biotin conjugates | |
EP1046401A2 (en) | Fatty acid derivative labelled with a radioactive transition metal | |
Panwar et al. | Synthesis of trans-1, 2-cyclohexyldinitrilo tetramethylene phosphonic acid and its radiolabelling with 99mTc for the detection of skeletal metastases | |
Försterová et al. | Complexation and biodistribution study of 111In and 90Y complexes of bifunctional phosphinic acid analogs of H4dota | |
US11723992B2 (en) | Method for extraction and purification of 68GA | |
EP0113135A2 (en) | Radiolabelled metallocene derivatives | |
JPH0797361A (en) | New chelate-forming compound and its use | |
US20140343260A1 (en) | Pet/spect agents for applications in biomedical imaging | |
Brown | Novel Dissymmetric Copper Bis (thiosemicarbazone) Complexes for Medical Diagnostic Imaging by Positron Emission Tomography. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010816 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20030214 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20030521 |